Effect of enhanced external counterpulsation treatment on renal function in cardiac patients

BMC Nephrology

Table 2 Outcomes of study patients after EECP treatment

Characteristics	Median (IQR)
	Baseline	End of 35^thsession	Follow-up
	(n = 30)	(n = 27)	(n = 30)
Systolic blood pressure (mm Hg)	122	120	130
	(113–133)	(110–130)	(120–130)
p-value		0.139^a	0.473^b
Diastolic blood pressure (mm Hg)	75	70	78
	(70–77)	(70–80)	(70–80)
p-value		0.839^a	0.431^b
Heart rate (beats/min)	70	68	71
	(61–75)	(59–80)	(63–80)
p-value		0.628^a	0.071^b
Creatinine (mg/dL)	1.02	0.97	1.01
	(0.84-1.36)	(0.8-1.34)	(0.85-1.36)
p-value		0.115^a	0.156^b
GFR (mL/min per 1.73 m²)	70.47	83.46	76.27
	(43.88-89.41)	(47.26-97.51)	(49.02-91.46)
p-value		0.075^a	0.006^b**
Cystatin C (mg/L)	1.00	0.91	0.94
	(0.78-1.31)	(0.77-1.39)	(0.77-1.27)
p-value		0.421^a	<0.001^b**
NT-proBNP (pg/mL)	244	200	210
	(120–1067)	(70–653)	(123–398)
p-value		0.416^a	0.425^b

^aEnd of 35^th session versus baseline, calculated using Wilcoxon signed ranks test.
^bFollow-up versus baseline, calculated using Wilcoxon signed ranks test.
(**)indicated statistically significant p-value less than 0.01.

ISSN: 1471-2369